Shares of RAPT Therapeutics (RAPT) plunged 46% Monday after the company said it was scrapping development of its drug ...

"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...

Fintel reports that on November 11, 2024, JP Morgan downgraded their outlook for RAPT Therapeutics (NasdaqGM:RAPT) from ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Rapt Therapeutics Inc ( (RAPT) ) has released its Q3 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its ...

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report), with a price target of $4.00. Yanan Zhu’s rating is based on RAPT ...

Author Sidney Morrison captivated a diverse audience at a recent speaking engagement at the Cleveland Public Library, ...

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether RAPT Therapeutics (NASDAQ:RAPT) ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.